Last reviewed · How we verify
H1 Antihistaminics
H1 Antihistaminics is a H1 receptor antagonist Small molecule drug developed by Erasmus Medical Center. It is currently FDA-approved for Allergic rhinitis, Urticaria, Pruritus.
H1 antihistaminics block histamine H1 receptors on cell surfaces, preventing histamine-mediated allergic and inflammatory responses.
H1 antihistaminics block histamine H1 receptors on cell surfaces, preventing histamine-mediated allergic and inflammatory responses. Used for Allergic rhinitis, Urticaria, Pruritus.
At a glance
| Generic name | H1 Antihistaminics |
|---|---|
| Sponsor | Erasmus Medical Center |
| Drug class | H1 receptor antagonist |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
These drugs competitively antagonize histamine at H1 receptor sites, which are distributed across smooth muscle, endothelium, and central nervous system tissues. By blocking H1 receptor signaling, they reduce vasodilation, bronchoconstriction, itching, and other acute allergic symptoms. First-generation agents cross the blood-brain barrier and cause sedation; second-generation agents are more selective for peripheral H1 receptors.
Approved indications
- Allergic rhinitis
- Urticaria
- Pruritus
- Allergic conjunctivitis
- Anaphylaxis (adjunctive)
Common side effects
- Sedation (first-generation agents)
- Dry mouth
- Headache
- Dizziness
- Anticholinergic effects
Key clinical trials
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (PHASE3)
- A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD) (PHASE3)
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (PHASE3)
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) (PHASE3)
- A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- H1 Antihistaminics CI brief — competitive landscape report
- H1 Antihistaminics updates RSS · CI watch RSS
- Erasmus Medical Center portfolio CI
Frequently asked questions about H1 Antihistaminics
What is H1 Antihistaminics?
How does H1 Antihistaminics work?
What is H1 Antihistaminics used for?
Who makes H1 Antihistaminics?
What drug class is H1 Antihistaminics in?
What development phase is H1 Antihistaminics in?
What are the side effects of H1 Antihistaminics?
What does H1 Antihistaminics target?
Related
- Drug class: All H1 receptor antagonist drugs
- Target: All drugs targeting Histamine H1 receptor
- Manufacturer: Erasmus Medical Center — full pipeline
- Therapeutic area: All drugs in Allergy/Immunology
- Indication: Drugs for Allergic rhinitis
- Indication: Drugs for Urticaria
- Indication: Drugs for Pruritus
- Compare: H1 Antihistaminics vs similar drugs
- Pricing: H1 Antihistaminics cost, discount & access